Matthew Cooper Email & Phone Number

Ann Arbor, Michigan, Us

CEO & Founder of Enumera Molecular, a life science tools company developing a single molecule detection platform capable of rapid, low cost assessment of biomolecules via liquid biopsy.

Menlo Park, Ca, Us

Avails Medical is developing solutions in accurate, rapid, and digital pathogen detection in bodily fluids to indicate effective drug treatments in real-time.For more information, visit https://availsmedical.com

Palo Alto, California, Us

StartX is a collection of serial entrepreneurs, industry experts, tenured Stanford professors, and well-funded growth-stage startups brought together via a non-profit community. We believe that entrepreneurs can achieve more as a group, than we can as individuals. We help our companies hire elite talent, secure funding, and tap into one of the most powerful and innovative networks in the world: the Stanford University Alumni Network and other StartX Founders.For more information, please visit: https://startx.com

NeoSeq is developing advanced technologies and comprehensive services for global healthcare needs, inclduing: ● Complete solution for non-invasive prenatal diagnostics -Lowest cost cell free fetal DNA based screening -Most advanced fetal cell technology for disease confirmation ● Cancer diagnostics -Liquid biopsy analysis through ctDNA and CTC -Early cancer screening ● Health risk assessment -Inherited diseaseshttp://www.neoseqltd.com for more information.

Full responsibility for all aspects of the Diagnostics business unit at Progenity.

Primary responsibilities include strategic and operational leadership of the R&D organization, Data Science, and IT. As Chairman of the corporate Portfolio Steering Committee, responsible for building an innovative product portfolio and pipeline, in addition to corporate strategy. During his tenure, Matt has lead an exceptionally productive R&D organization, delivering a robust pipeline of innovative products yielding hundred of millions of dollars in lifetime revenue, including:- Preparent (global carrier screening) 2nd generation and 3rd generation o Significantly expanding content whilst reducing COGS- Riscover o Low COGS, heritable cancer genetic test- Innatal 1 o Internalization of NGS-based NIPT- Innatal 2 o Proprietary NIPT with best-in-class performance and low COGS- Resura o First-in-class monogenic disease detection using maternal blood sample- Preecludia o First-in-class rule-out test for Preeclampsia

Melbourne, Fl, Us

Member of the board of directors for a national patient advocacy organization, serving over 200,000 pregnany women each year who suffer from hypertensive disorders of pregnancy.

Palo Alto, Ca, Us

Evaluate IP from Stanford College of Medicine program for development and commercialization. http://sparkmed.stanford.edu/

San Francisco, California, Us

Advise Lean LaunchPad faculty on curriculum and business case applications of lean launchpad concepts in the life science industry.Mentor life science start-ups in the Lean LaunchPad program. Assist life start-up founders in commercializing their scientific discoveries via customer development and lean start-up methodologies.http://ita.ucsf.edu/entrepreneurship-center/education/courses/lean-launchpad-life-science-healthcare

Acquired by Progenity Apr2015Founder and CEO of Carmenta Bioscience, a biotechnology company dedicated to addressing unmet medical needs in maternal and fetal health, with a focus on development and commercialization of diagnostic tests for preeclampsia. Co-founded by Atul Butte and Bruce Ling from Stanford School of Medicine.Raised >$2M in an oversubscribed seed round (http://www.businesswire.com/news/home/20130807005422/en/Carmenta-Bioscience-Secures-2-Million-Oversubscribed-Seed) and then acquired 18 months later by Progenity (http://www.businesswire.com/news/home/20150429005191/en/Progenity-Acquires-Carmenta-Bioscience-Proprietary-Preeclampsia-Technology).

San Francisco, Ca, Us

Responsible for translating customer's scientific and strategic needs into actionable software development goals. Other responsibilities include:• Customer development• Identification and management of strategic partnerships • Corporate strategy• Management of scientific talent

Switzerland 🇨🇭 , Ch

Responsible for leading all strategic and operational aspects of non-clinical safety information globally. Also responsible for identifying and collaborating with key technology partners in the industry and academia. Reported directly to Global Head of Non-Clinical Safety and served on the Core Global Leadership Team. Matthew also served on the RIST (Roche Informatics Steering Team), a decision making body that governed strategic investments in informatics for Roche Pharma globally.

Switzerland 🇨🇭 , Ch

Discovery & Investigative Safety group with Non Clinical Safety.My job responsibilities are 3-fold: 1. Lead early safety assessments for the therapeutic protein portfolio in Palo Alto. Act as immunosafety coordinator for site (50% effort).2. Lead the development and deployment of informatics strategies to support the Non Clinical Safety department; serve as chair of the Data Management working group for the Critical Path Institute (25% effort).3. Conduct investigational toxicology projects to address safety issues for both biologics and small molecules (25% effort).

Cambridge, Ma, Us

Biomarker scientist, also group leader for Transcript Profiling and Computational Biology within Preclinical Development Sciences department.

Cambridge, Ma, Us

Project Toxicologist: worked on development teams to support drug registration activities. Tasks included designing, monitoring, and reporting of nonclinical safety studies, contributing to INDs and end of Phase II documents, and performing toxicogenomic and other investigational safety evaluations.

New York, Ny, Us

Worked with brokers to create portfolio reports for high wealth clients. Liaised with high wealth clients regarding biotechnology and pharmaceutical companies, providing “plain English” explanations of product pipelines.

Midland, Michigan, Us

Established the high-throughput “Ames II” assay for genotoxicity screening. Also cloned human cytochrome P450 enzymes into Ames bacterial strains to assist in the evaluation of human-specific mutagens.

Cincinnati, Ohio, Us

Performed CHO cell chromosomal aberration assay in corporate toxicology group.

Mba, Finance, General

Mba, Entrepreneurship

Ph.D., Toxicology

B.S., Chemistry (College Of Engineering)